Analysis and assessment of relationship between the expression levels of ras oncogane product p21 in carcinomas of oral mucosa and their clinical tuma status
口腔黏膜癌ras癌基因产物p21表达水平与临床肿瘤状态的关系分析与评估
基本信息
- 批准号:62570901
- 负责人:
- 金额:$ 1.22万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1987
- 资助国家:日本
- 起止时间:1987 至 1988
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
1. We examined the expression of ras p21 in tissue sections from 121 patients with squamous cell head and neck cancer using monoclonal antibody and immunohisto chemical nethod. Among the 121 patients examined, 59 specimens showed positive staining ras p21. On the hand, no 44 oral leukoplakies and 58 normal mucosae were seen to be positivaly stained. A total of 43 patients including 27 treated, tumor-free cases, who have been follored for at least 5 years and 16 dead cases, were analyzed for the relationship hetween ras p21 expression in the primary tumor sites and clinical outcome in relation to the clinico pathological tumor status. The expression of ras p21 in 43 patients was significantly poor prognesis at p<0.001. When 121 patients were analyzed in relation to the histological graling, ras p21 expression in grade I+II and grade III was significantly poor prognosis at p<0.05 and p.0.0005, respectively. In addition, correlation hetween ras p21 expression and poor prognosis with regar … More d to the clinical staging was signifiasnt in stage III (p<0.05) and stage III+IV (p<0.005). The examination of relationship hstween ras p21 expression in the primary tumors and regional lyngsh node netostasis resulted in statistical significance (p<0.06). Moreover, expression of ras p21 in the 43 pateints showed significant relation with tohacco use. These findings suggest that ras p21 expression in squamous cell head and neck cancer tissue is conelated with the clinico pathological tumor status and clinical outcome.2. Ras oncogene product p21 expression in fresh tumor tissue from a squamous cell careinoma of the naeillary sincos was examined by the use of immunoparoxidase staining and immunoflotting. As a consequence, expression of ras p21 in tissue sections taken at pretreatment time showed strongly positive stain. However, the content of ras p21 present in the tumor tissues obtained after completion of cancer treatment was markedly reduced, when compared with the hicpsy material. These findiags indicate that effect of some cancer therapy could he estimated from ras p21 expression in tumor tissues.3. A human salivary qland sdenecarinoma cell line, HSG, expresses ras oncogend p21 at a high level. When HSG cells were cultured in the presence of dibutyigl cyclic AMP (dB-cAMP), it was shown that colonyforming ability of HSG cells was suppressed in accordance with the concentration of added dB-CAMP. In additon, ras p21 expression in the treated HSG cells was reduced, when compared with the untreated HSG cells. Moreover, it was found that conelation hetween the concentralions of dB-CAMP and intracellular cAMP in the HSG cells was statistically significant. Less
1.应用单克隆抗体和免疫组化方法检测了121例头颈鳞癌组织中rasp 21的表达。在121例患者中,59例ras p21阳性。44例口腔粘膜白斑和58例正常口腔粘膜均未见阳性染色。本文分析了43例原发性肝癌患者(其中27例经治疗,无瘤,随访5年以上,16例死亡)原发灶ras p21表达与临床病理结果的关系。43例ras p21阳性表达者预后差,P<0.001。当分析121例患者与组织学分级的关系时,rasp 21表达在I+II级和III级中分别是显著不良预后,p<0.05和p <0.0005。此外,rasp 21表达与预后不良之间的相关性与regar ...更多信息 d与临床分期的关系在Ⅲ期(p<0.05)和Ⅲ + Ⅳ期(p<0.005)无显著性差异。原发灶ras p21表达与淋巴结转移的关系有统计学意义(p<0.06)。ras p21蛋白表达与激素使用密切相关。提示rasp 21在头颈部鳞状细胞癌组织中的表达与肿瘤的临床病理状态及临床预后有关.应用免疫过氧化物酶染色和免疫印迹法检测了1例鼻咽癌新鲜组织中Ras癌基因产物p21的表达。结果,在预处理时间取的组织切片中ras p21的表达显示强阳性染色。然而,与打嗝材料相比,癌症治疗完成后获得的肿瘤组织中存在的ras p21含量显着降低。这些结果提示,rasp 21在肿瘤组织中的表达可以作为某些肿瘤治疗效果的评价指标.人唾液腺腺癌细胞系HSG高水平表达ras癌基因p21。当HSG细胞在存在二丁基环腺苷酸(dB-cAMP)的情况下培养时,显示HSG细胞的集落形成能力根据所添加的dB-cAMP的浓度而受到抑制。另外,与未经处理的HSG细胞相比,经处理的HSG细胞中ras p21表达降低。此外,还发现HSG细胞内的dB-cAMP浓度与细胞内cAMP浓度之间有显著性差异。少
项目成果
期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Masayuki Azuma: "The relation of ras oncogone product p21 expression to clinicopathological status criteria and clinical outcome in squamous cell head and neck carcer" The Cancer J.1. 375-380 (1987)
Masayuki Azuma:“鳞状细胞头颈癌中 ras 癌基因产物 p21 表达与临床病理状态标准和临床结果的关系”The Cancer J.1。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
東雅之: 日本虚空外科学会雑誌. 33. 1710-1716 (1987)
Masayuki Azuma:日本虚空外科学会杂志 33. 1710-1716 (1987)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Masayuki Azuma: "Expression of ras oncogone product p21 in maxillary cancer tissues" Jpr. J. Oral Maxillofac. Surg.33. 1710-1716 (1987)
Masayuki Azuma:“ras oncogone 产物 p21 在上颌癌组织中的表达”Jpr。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Masayuki Azuma: "Cellular proliferation and ras oncogone of p21 21,000 expression in relation to the intracellular cyclic aclonosine 3':5'-monophosphate lovels of human salivary gland adeno carinoma cell line in culture" Cancer Res.47. 2898-2903 (1988)
Masayuki Azuma:“p21 21,000 表达的细胞增殖和 ras oncogone 与培养的人唾液腺腺癌细胞系的细胞内环阿克洛苷 3:5-单磷酸盐相关”Cancer Res.47。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AZUMA Masayuki其他文献
AZUMA Masayuki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AZUMA Masayuki', 18)}}的其他基金
Development of a novel treatment for Sjogren's syndrome on the basis of the regulation of molecules related to the syndrome
基于干燥综合征相关分子调节的新型治疗方法的开发
- 批准号:
17K11842 - 财政年份:2017
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of the microbial catalyst suitable for a bio-fuel cell by integrating superior functions in Escherichia coli
通过整合大肠杆菌的卓越功能开发适用于生物燃料电池的微生物催化剂
- 批准号:
26420797 - 财政年份:2014
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel histopathology of oral lichen plans and its therapeutic strategy
口腔苔藓的新型组织病理学及其治疗策略
- 批准号:
24659896 - 财政年份:2012
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Study to raise the performance of the glucose fuel cell "Improvement of the electronic acquisition technology from the microbe in the fuel cell"
提高葡萄糖燃料电池性能的研究“燃料电池中微生物电子获取技术的改进”
- 批准号:
22560773 - 财政年份:2010
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Exploration of oral cancer-specific biomarkers by profiling of NF-KB-dependent molecules
通过分析 NF-KB 依赖性分子来探索口腔癌特异性生物标志物
- 批准号:
20592362 - 财政年份:2008
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of an antilymphangiogenesis through the regulation of NFtB signaling in oral cancer
通过调节口腔癌中的 NFtB 信号传导来开发抗淋巴管生成药物
- 批准号:
18592221 - 财政年份:2006
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a novel combined chemotherapy in head and neck cancer-combination of a DNA demethylating agent and an anticancer agent-
开发头颈癌新型联合化疗——DNA去甲基化剂和抗癌剂的组合——
- 批准号:
15390617 - 财政年份:2003
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mechanisms involved in the anti-tumor effect of introduction of a mutant from of I_KBα gene into human oral cancer cells
I_KBα基因突变体导入人口腔癌细胞的抗肿瘤作用机制
- 批准号:
13672102 - 财政年份:2001
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study for both the establishment of in vivo model system for the development of salivary mucous cyst and its treatment
唾液腺粘液囊肿体内模型系统的建立及其治疗研究
- 批准号:
06557112 - 财政年份:1994
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
Establishment of highly metastasizing human salivary gland cancer cell lines and the analysis of mechanisms involved in the metastasis
人唾液腺癌细胞高转移株的建立及转移机制分析
- 批准号:
05671673 - 财政年份:1993
- 资助金额:
$ 1.22万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)